NAŘÍZENÍ XXXXXX (XX) 2021/383
xx dne 3.&xxxx;xxxxxx 2021,
xxxxxx xx xxxx xxxxxxx III xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1107/2009 uvedením xxxxxxx xxxxxxxxxxxx přísad, xxxxx jsou nepřijatelné xxxx xxxxxxx xxxxxxxxx xx ochranu xxxxxxx
(Xxxx x&xxxx;xxxxxxxx xxx XXX)
XXXXXXXX XXXXXX,
x&xxxx;xxxxxxx xx Xxxxxxx x&xxxx;xxxxxxxxx Xxxxxxxx xxxx,
x&xxxx;xxxxxxx xx nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (ES) x.&xxxx;1107/2009 xx dne 21.&xxxx;xxxxx&xxxx;2009 x&xxxx;xxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxx xx xxx a o zrušení xxxxxxx Xxxx 79/117/EHS x&xxxx;91/414/XXX&xxxx;(1), x&xxxx;xxxxxxx xx xx.&xxxx;27 odst. 2 x&xxxx;xx.&xxxx;78 xxxx.&xxxx;2 xxxxxxxxx nařízení
vzhledem x&xxxx;xxxxx xxxxxxx:
|
(1) |
Xxxxxxxxxx xxxxxxx xxxx xxxxxxx v čl. 2 xxxx.&xxxx;3 xxxx. x) xxxxxxxx (ES) č. 1107/2009 jako xxxxx xx xxxxxxxxx, xxxxx se xxxxxxxxx x&xxxx;xxxxxxxxxxx xx xxxxxxx xxxxxxx xx v adjuvantech xxxx xxxx x&xxxx;xxxxxxxx xxxxxxx určeny, xxxxx xxxxx xxxxxxx xxxx xxxxxx látky, safenery xxx xxxxxxxxxx. |
|
(2) |
Xxxxxxxxxx xxxxxxx xxxx xxxxxxxxxxxx xxxx xxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxx, xxxxx xxxxxx rezidua, xxxxx xxxxxxx xx aplikaci x&xxxx;xxxxxxx se xxxxxxxx xxxxx x&xxxx;xxxxxxx xxxxxxx xxx zohlednění xxxxxxxxxx xxxxxxxx použití, xxxx xxxxxxxx účinky xx xxxxxx lidí xxxx xxxxxx anebo xx xxxxxxxx xxxx či xxxxxxxxxxxx xxxxxx xx xxxxxxx xxxxxxxxx. Formulační xxxxxxx xxxx xxxxxx xxxxxxxxxxxx xxxx xxxxxxx xxxxxxxxx na ochranu xxxxxxx, pokud jejich xxxxxxxxx po xxxxxxxx x&xxxx;xxxxxxx se xxxxxxxx xxxxx v ochraně xxxxxxx xxx xxxxxxxxxx skutečných xxxxxxxx xxxxxxx má xxxxxxxx xxxxxx xx xxxxxx lidí xxxx xxxxxx anebo xxxxxxxxxxxx xxxxxx xx xxxxxxxx, xxxxxxxxx produkty xxxx xxxxxxx xxxxxxxxx. Takové xxxxxxxxxxxx xxxxxxxxxx přísady xxxx xxx xxxxxxx xx seznamu x&xxxx;xxxxxxx XXX xxxxxxxx (ES) x.&xxxx;1107/2009. |
|
(3) |
Xxxxxxxxxx přísady xxxx xxxxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxx x&xxxx;xxxxxxxx xxxxxxx x&xxxx;xxxxxxxxxxx xx xxxxxxx xxxxxxx, x&xxxx;xxxx xxxxx rovněž xxxxxx x&xxxx;xxxxxxxx xxxxxxxxx. Xxxxx xx kritéria xxxxxxxx xx xxxxxxxx xxxxxx, xxxxxxxxx prostředí, xxxxxxxxxxx x&xxxx;xxxxxxxxxx xxx stanovená x&xxxx;xxxxxx 3.6.2, 3.6.3, 3.6.4, 3.6.5, 3.7, 3.8.2 x&xxxx;3.10 xxxxxxx XX nařízení (ES) x.&xxxx;1107/2009 xxxx být xxxxxx relevantní xxx xxxxxxxxxxxx xxxxxxxxxxxxxx formulačních xxxxxx. |
|
(4) |
Xxxxxx xxxxxxxxxxxxxx formulačních xxxxxx xx měl xxxxx zahrnovat xxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxxx, xxxxxxxxx 1&xxxx;X&xxxx;xxxx 1X, jako mutageny, xxxxxxxxx 1 A nebo 1X, xxxx jako toxické xxx xxxxxxxxxx, kategorie 1&xxxx;X&xxxx;xxxx 1X, x&xxxx;xxxxxxx x&xxxx;xxxxxxxx XX xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1272/2008&xxxx;(2). |
|
(5) |
Xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxx xx xxx dále zahrnovat xxxxx identifikované xxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx x&xxxx;xxxxxxx („XXX“) nebo xxxxxx xxxxxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxxxxxxx („xXxX“) v souladu x&xxxx;xx.&xxxx;57 xxxx. x) a e) xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1907/2006&xxxx;(3). |
|
(6) |
Xxxxxx xxxxxxxxxxxxxx formulačních xxxxxx xx xxx xxxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxx v důsledku xxxxxxxxxx xxxxxxxxxxxxxx narušení xxxxxxxxxx činnosti v souladu x&xxxx;xx.&xxxx;57 písm. x) xxxxxxxx (XX) x.&xxxx;1907/2006 xxxx látky identifikované xxxx endokrinní xxxxxxxxxx xxxxx nařízení Evropského xxxxxxxxxx a Rady (XX) x.&xxxx;528/2012&xxxx;(4) xxxx xxxxx xxxxxxxxxxxxxx xxxx perzistentní xxxxxxxxx xxxxxxxxxxxx xxxxx („XXX“) podle xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady (XX) 2019/1021&xxxx;(5). |
|
(7) |
Xxxxxxxx (XX) x.&xxxx;1907/2006 xxxxxxx x&xxxx;xxxxxxx XXXX omezení xxx xxxxxxx nebezpečné xxxxx. Xxxxxxx-xx xxxxxxx xxxxxxxxx xxxxx jakožto xxxxxxxxxxxx xxxxxx x&xxxx;xxxxxxxxxxx xx xxxxxxx rostlin xxxxxxxx, xxxx xx xxx xxxxxxxx xx seznam xxxxxxxxxxxx xxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (XX) x.&xxxx;1107/2009. |
|
(8) |
Xxxxxxx xxxxx xxxxxxxxxxxxxx xxxxxxxxxx přísady, které xxxxxxxx xx xxxxxxxxxxxx x&xxxx;xxxxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxxx xxxxx xxxxxxxx Xxxx 91/414/XXX&xxxx;(6) xxxx xxxxxxxx (XX) x.&xxxx;1107/2009. Xxxxxx formulační xxxxxxx xxxxxxxx Rakousko, Xxxxxx, Xxxxxxx, Xxxxxxx, Xxxxxx, Xxxxx, Xxxxxxxxx x&xxxx;Xxxxxx. X&xxxx;xxxxxxxxx xxxxxxxxxxxx xxxxxx by xxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxxx, xxxxxxxxx 1&xxxx;X&xxxx;xxxx 1X, jako mutageny, xxxxxxxxx 1 A nebo 1B, xxxx jako xxxxxxx xxx xxxxxxxxxx, xxxxxxxxx 1&xxxx;X&xxxx;xxxx 1X, v souladu x&xxxx;xxxxxxxx VI xxxxxxxx (XX) č. 1272/2008, xxxxxxx xxxxxxxxxxxxxx jako XXX xxxx vPvB podle xx.&xxxx;57 xxxx. x) x&xxxx;x) xxxxxxxx (XX) x.&xxxx;1907/2006, xxxxxxx identifikované xxxx látky vzbuzující xxxxxxxxx xxxxx v důsledku xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx x&xxxx;xxxxxxx x&xxxx;xx.&xxxx;57 písm. x) xxxxxxxx (XX) č. 1907/2006 x&xxxx;xxxxxxx xxxxxxxxxxxxxx jako XXX xxxxx nařízení (XX) 2019/1021 xxxx xxx xxxxxxx xx xxxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (ES) x.&xxxx;1107/2009. |
|
(9) |
Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxx (x.&xxxx;XXX 61791-26-2) v přípravcích xx xxxxxxx xxxxxxx xxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxxx Xxxxxx (XX) 2016/1313&xxxx;(7), xxxxxxx xxxx xxxxxxxx xxxxx x&xxxx;xxxxxxxxxxx s toxicitou xxxxxxxxxxxxxx aminů xxxx x&xxxx;xxxxxx potenciálem xxx xxxxxxxxx vliv na xxxxxx zdraví. Xxxxxxxx x&xxxx;xxxx, že uvedené xxxxx vyplývají x&xxxx;xxxxxxxxxxx xxxxxxxxxx dotčených xxxxx, x&xxxx;xx xxxxx nejsou xxxxxxx na xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx glyfosát, xxx xxxx stejnou xxxxxxxx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxxx, měly xx být ethoxylované xxxxx xxxx xxxxxx xxxxxxxx xx xxxxxx xxxxxxxxxxxx xxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (XX) x.&xxxx;1107/2009. |
|
(10) |
Xxxxxxxxxxx xxxxxxxxxxxx Xxxxxx (XX) 2016/109&xxxx;(8) a (EU) 2018/619&xxxx;(9) xxxxxx schváleny xxxxx XXXX (1600; 1.8), xxxxx XXX 27083-27-8 x&xxxx;32289-58-0, a PHMB (1415; 4.7), číslo XXX 32289-58-0 x&xxxx;1802181-67-4, xxxx xxxxxxxxx xxxxxx xxxxx xxx použití x&xxxx;xxxxxxxxxx přípravcích xxxx 6 (xxxxxxxxxxx xxx xxxxxxx x&xxxx;xxxxxxxxxx obalech), xxxx xxxxxx typy xxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxxxxxxx xxxxx pro xxxxxx xxxxxx x&xxxx;xxxxxxx xxxxxxxxx. Xxxxxx xxxxxxx xxxx xxxxxxxxxxx pro xxxxxxx x&xxxx;xxxxxxxxxx obalech v přípravcích xx xxxxxxx xxxxxxx xx xxxxx vedlo x&xxxx;xxxxxxxxxxxxx účinkům na xxxxxx xxxxxx x&xxxx;xxxxxxx xxxxxxxxx. Xxxxx by xxxxx PHMB (1600; 1.8) x&xxxx;XXXX (1415; 4.7) xxxx xxx xxxxxx xxxxxxx xx xxxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (XX) x.&xxxx;1107/2009. |
|
(11) |
Xxxxxxxxxx xxxxxxx, které xxxx xxx xxxxxxx xx xxxxxxx v příloze XXX xxxxxxxx (XX) x.&xxxx;1107/2009 xxxxx být xxxxxx xxxxxxxx x&xxxx;xxxxxxxxxxx xxxxxxxxx xx xxx. Xxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx pro xxxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxx x&xxxx;xx.&xxxx;58 odst. 2 xxxxxxxx (XX) x.&xxxx;1107/2009, xxxxx xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx se xxxxxxxxx, xxxxx jsou v souladu x&xxxx;xx.&xxxx;81 xxxx.&xxxx;3 xxxxxxxxx xxxxxxxx. Xxxxxxx xxxxxxxx (XX) x.&xxxx;1107/2009 xx xx xxx zabránit xxxxxxx xx trh xxxx používání adjuvantů xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxx, xxx xxxxxx xxxxxxxxx, xxxxx xxxx xxx smíseny x&xxxx;xxxxxxxxx xx xxxxxxx xxxxxxx, xxxxxxxxxxxx žádné x&xxxx;xxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxx. |
|
(12) |
Xxxxxxxx xxxxxx by měl xxx xxxxxxxxx dostatek xxxx na xxxxxxx xxxxxxx xxxxxxxxx na xxxxxxx xxxxxxx a adjuvantů, xxxxx xxxx x&xxxx;xxxxxxxxxxx xxxxxxxx na xxxxxx xxxxx, xxx xxxxx xxxxxxxx, xxx xxxxxxxx xxxxxxxxxx xxxxxxx uvedené xx xxxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (ES) x.&xxxx;1107/2009, x&xxxx;xxx xxxxx xxxxxxxx xxxx změnit xxxxxxxx xxxxxxxxx na xxxxxxx rostlin x&xxxx;xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx. |
|
(13) |
X&xxxx;xxxxxxxxx xx ochranu xxxxxxx nebo adjuvantů xxxxxxxxxxxx formulační xxxxxxx xxxxxxxx xx xxxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (XX) x.&xxxx;1107/2009, xxx xxx xxxxxxx xxxxx xxxxx xxxxxxxxxx odkladnou xxxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxx&xxxx;46 xxxxxxxxx xxxxxxxx nebo xxxxxxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx xxx xxxxxxxxxx xxxxxxxxx, by uvedená xxxxx měla uplynout xxx xxxxxx x&xxxx;xxxxxxxxxx xxxxxxxxxx za tři xxxxxx x&xxxx;xxx xxxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxxx za xxxxxxx xxxxx měsíců xx datu xxxxx xxxx xxxxxx povolení. |
|
(14) |
Formulační xxxxxxx, xxxxx xxxx xxx xxxxxxx na xxxxxxx x&xxxx;xxxxxxx III xxxxxxxx (XX) x.&xxxx;1107/2009, xxxxx xxx přítomny xxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxxxx přísadách, xxxxx xxxx jako xxxxxx xxxxxxxxxx pro xxxxxxx v přípravcích xx xxxxxxx xxxxxxx xxxx xxxxxxxxxxx. Proto xx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxx přísad x&xxxx;xxxxxxxx xxxxxxxxx xx ochranu xxxxxxx xxxx xxxxxxxxx xxxx být xxxxx xxx 0,1&xxxx;% xxxxxxxxxxxx (xxxx.) xxxx xxxxx xxx specifický xxxxxxxxxxxx xxxxx týkající xx XXX xxxxxxxxxx (xxxxxxxxxxxxxx, xxxxxxxxxxx x&xxxx;xxxxxxxxx pro xxxxxxxxxx), xx-xx xxxxxxxx x&xxxx;xxxxxxx XX nařízení (XX) x.&xxxx;1272/2008 pro xxxxxxxxxxxxx formulační xxxxxxx xx úrovni nižší xxx 0,1 % xxxxxxxxxxxx (xxxx.), aby xxxx xxxxx je považovat xx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx, pokud xxxx x&xxxx;xxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxx analytických xxxxx xxxxxxxx jiný limit. |
|
(15) |
Opatření xxxxxxxxx xxxxx nařízením xxxx x&xxxx;xxxxxxx xx xxxxxxxxxxx Stálého xxxxxx xxx xxxxxxxx, xxxxxxx, xxxxxxxxx x&xxxx;xxxxxx, |
XXXXXXX XXXX XXXXXXXX:
Xxxxxx&xxxx;1
Xxxxxxx III xxxxxxxx (XX) č. 1107/2009 xx xxxx v souladu s přílohou xxxxxx xxxxxxxx.
Xxxxxx&xxxx;2
Xxxxxxx xxxxx, xxxxx xxxxxxx xxxxxxxx xxx xxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxx xx xxxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (XX) x.&xxxx;1107/2009, xx xxxxx xxxxxx xxxxxxxx, uvedená povolení xxxxx xxxx xxxxxxx xx nejdříve, avšak xxxxxxxxxx xx 24.&xxxx;xxxxxx 2023.
Xxxxxx&xxxx;3
Xxxxxxx státy xxxxxxxx xxxxxxx na trh xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxx na xxxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (XX) x.&xxxx;1107/2009, ve xxxxx tohoto xxxxxxxx.
Xxxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx obsahující xxxxxxxxxx xxxxxxx xxxxxxx xx xxxxxxx v příloze XXX xxxxxxxx (ES) x.&xxxx;1107/2009, xx xxxxx tohoto xxxxxxxx, uvedená xxxxxxxx xxxxx xxxx odejmou xx nejdříve, avšak xxxxxxxxxx xx 24.&xxxx;xxxxxx 2023.
Xxxxxx&xxxx;4
Xxxxxxxxx xxxxxxxx lhůta xxxxxxx členskými xxxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxx&xxxx;46 xxxxxxxx (XX) č. 1107/2009 nebo xxxxxxxxxxxxxx xxxxxxxx xxx xxxxxxxxxx adjuvantů xxxx xxx xx nejkratší x&xxxx;xxxx xxxxxxxx xxx xxxxxx x&xxxx;xxxxxxxxxx xxxxxxxxxx xx xxx xxxxxx x&xxxx;xxx odstranění, skladování x&xxxx;xxxxxxx xx dalších xxxxx xxxxxx po xxxx změny xxxx xxxxxx xxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxx 2 a 3.
Xxxxxx&xxxx;5
Xxxx xxxxxxxx xxxxxxxx x&xxxx;xxxxxxxx xxxxxxxx xxxx xx xxxxxxxxx v Úředním xxxxxxxx Xxxxxxxx xxxx.
Xxxx xxxxxxxx xx xxxxxxx x&xxxx;xxxxx rozsahu x&xxxx;xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx xxxxxxx.
X&xxxx;Xxxxxxx xxx 3.&xxxx;xxxxxx 2021.
Xx Xxxxxx
xxxxxxxxxxx
Xxxxxx XXX XXX XXXXX
(1)&xxxx;&xxxx;Xx. věst. X&xxxx;309, 24.11.2009, s. 1.
(2) Nařízení Evropského xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1272/2008 xx xxx 16.&xxxx;xxxxxxxx&xxxx;2008 o klasifikaci, označování x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx, x&xxxx;xxxxx x&xxxx;xxxxxxx směrnic 67/548/XXX x&xxxx;1999/45/XX x&xxxx;x&xxxx;xxxxx xxxxxxxx (XX) č. 1907/2006 (Xx. věst. X&xxxx;353, 31.12.2008, x.&xxxx;1).
(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (ES) x.&xxxx;1907/2006 xx xxx 18.&xxxx;xxxxxxxx&xxxx;2006 o registraci, hodnocení, xxxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxx, o zřízení Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x&xxxx;xxxxx xxxxxxxx 1999/45/XX x&xxxx;x&xxxx;xxxxxxx xxxxxxxx Xxxx (EHS) x.&xxxx;793/93, xxxxxxxx Komise (ES) x.&xxxx;1488/94, xxxxxxxx Rady 76/769/XXX x&xxxx;xxxxxxx Xxxxxx 91/155/XXX, 93/67/EHS, 93/105/XX x&xxxx;2000/21/XX (Úř. xxxx. X&xxxx;396, 30.12.2006, x.&xxxx;1).
(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady (XX) č. 528/2012 xx xxx 22.&xxxx;xxxxxx&xxxx;2012 o dodávání xxxxxxxxxx xxxxxxxxx na xxx a jejich xxxxxxxxx (Xx. xxxx. X&xxxx;167, 27.6.2012, x.&xxxx;1).
(5)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) 2019/1021 ze xxx 20.&xxxx;xxxxxx&xxxx;2019 o perzistentních xxxxxxxxxxx xxxxxxxxxxxxxx látkách (Xx. xxxx. X&xxxx;169, 25.6.2019, x.&xxxx;45).
(6)&xxxx;&xxxx;Xxxxxxxx Xxxx 91/414/XXX xx dne 15. července 1991 x&xxxx;xxxxxxx xxxxxxxxx na xxxxxxx xxxxxxx xx xxx (Xx. věst. X&xxxx;230, 19.8.1991, s. 1).
(7) Prováděcí xxxxxxxx Xxxxxx (EU) 2016/1313 xx xxx 1.&xxxx;xxxxx&xxxx;2016, xxxxxx xx xxxx xxxxxxxxx xxxxxxxx (XX) x.&xxxx;540/2011, pokud xxx x&xxxx;xxxxxxxx xxxxxxxxx xxxxxx xxxxx glyfosátu (Xx. věst. L 208, 2.8.2016, x.&xxxx;1).
(8)&xxxx;&xxxx;Xxxxxxxxx rozhodnutí Xxxxxx (XX) 2016/109 xx dne 27. ledna 2016 x&xxxx;xxxxxxxxxxx PHMB (1600; 1.8) jako stávající xxxxxx xxxxx xxx xxxxxxx x&xxxx;xxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxx xxxx xxxxxxxxx 1, 6 x&xxxx;9 (Úř. xxxx. X&xxxx;21, 28.1.2016, x.&xxxx;84).
(9)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxxxx Xxxxxx (XX) 2018/619 xx xxx 20.&xxxx;xxxxx&xxxx;2018 x&xxxx;xxxxxxxxxxx PHMB (1415; 4.7) jako xxxxxxxxx xxxxxx xxxxx xxx xxxxxxx x&xxxx;xxxxxxxxxx xxxxxxxxxxx typu 1, 5 a 6 (Xx. xxxx. X&xxxx;102, 23.4.2018, x.&xxxx;21).
PŘÍLOHA
Příloha XXX nařízení (XX) x.&xxxx;1107/2009 xx xxxxxxxxx tímto:
„PŘÍLOHA XXX
Xxxxxx xxxxxxxxxxxx xxxxxx, xxxxx xxxx xxxxxxxxxxxx jako xxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxx, xxxxxxx x&xxxx;xxxxxx&xxxx;27&xxxx;&xxxx;(1)
|
X. |
Xxxxx |
Xxxxx XX/xxxx xxxxx |
Xxxxx XXX |
Xxxxx XX |
Xxxxxxxxxxx/xxxx vlastnosti |
|
1. |
1-chlor-2,3-epoxypropan |
epichlorhydrin; 2,3-xxxxxxxxxxx-xxxxxxx |
106-89-8 |
203-439-8 |
xxxxxxxxxxxx xxx. 1B |
|
2. |
1,2-dichlorethan |
1,2-dichlorethan; ethan, 1,2-xxxxxxx- |
107-06-2 |
203-458-1 |
xxxxxxxxxxxx xxx. 1B |
|
3. |
2-ethoxyethanol |
2-ethoxyethanol; ethanol, 2-xxxxxx- |
110-80-5 |
203-804-1 |
xxxxxxx pro xxxxxxxxxx xxx. 1B |
|
4. |
2-ethoxyethyl-acetát |
2-ethoxyethanol-acetát; xxxxxxx, 2-xxxxxx-, 1-acetát |
111-15-9 |
203-839-2 |
toxické xxx xxxxxxxxxx xxx. 1X |
|
5. |
1-xxxxxxxxxxxxxxx-2-xx |
1-xxxxxxxxxxxxxxx-2-xx; X-xxxxx-2-xxxxxxxxxx |
2687-91-4 |
220-250-6 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
6. |
2-xxxxxxxxxxxxxx |
2-xxxxxxxxxxxxxx; xxxxxxx, 2-xxxxxxx- |
109-86-4 |
203-713-7 |
xxxxxxx pro xxxxxxxxxx xxx. 1X |
|
7. |
2-xxxxxxxxxxxx-xxxxxx |
2-xxxxxxxxxxxx-xxxxxx; xxxxxxx, 2-xxxxxxx-, 1-acetát; 2-methoxyethanol-acetát |
110-49-6 |
203-772-9 |
toxické xxx xxxxxxxxxx xxx. 1X |
|
8. |
2-xxxxxxxxxxxxx-1-xx |
2-xxxxxxxxxxxxx-1-xx; 1-xxxxxxxx, 2-xxxxxxx- |
1589-47-5 |
216-455-5 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
9. |
1-xxxxxxxxxxxxxxxx-2-xx |
1-xxxxxx-2-xxxxxxxxxx; 2-xxxxxxxxxxxx, 1-xxxxxx- |
872-50-4 |
212-828-1 |
xxxxxxx xxx reprodukci xxx. 1X |
|
10. |
2-xxxxxxxxxxx |
2-xxxxxxxxxxx; xxxxxx, 2-xxxxx- |
79-46-9 |
201-209-1 |
xxxxxxxxxxxx xxx. 1X |
|
11. |
xxxxxxxxxx xxxx, xxxxxxxxxxxx |
xxxxxxxxxx xxxx, ethoxylované; ethoxylovaný amin xxxx |
61791-26-2 |
xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxxxxxx xxxxxx na lidské xxxxxx nebo xxxxxxx xxxxxxxxx |
|
|
12. |
xxxxxxxxxx loje, ethoxylované x&xxxx;xxxxxxxxxxxxx |
xxxxxxxxxx xxxx, xxxxxxxxxxxx x&xxxx;xxxxxxxxxxxxx; xxxxxxxxxxxx a propoxylovaný xxxx xxxx |
68213-26-3 |
xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxxx s potenciálními xxxxxx xx xxxxxx xxxxxx xxxx životní xxxxxxxxx |
|
|
13. |
xxxxxxxxx xxxxxx |
xxxxxxxxxxxx xxxxxx; xxxxxx, xxxxxxxxxxxx |
77536-66-4 |
xxxxxxxxxxxx xxx. 1 A |
|
|
14. |
amositový xxxxxx; xxxxxx, xxxxxxxxx |
12172-73-5 |
xxxxxxxxxxxx kat. 1&xxxx;X |
||
|
15. |
xxxxxxxxxxxx azbest; azbest, xxxxxxxxxxxx |
77536-67-5 |
xxxxxxxxxxxx xxx. 1&xxxx;X |
||
|
16. |
xxxxxxxxxxxx azbest; azbest, xxxxxxxxxxxx |
12001-29-5 |
xxxxxxxxxxxx xxx. 1&xxxx;X |
||
|
17. |
xxxxxxxxxxxxx xxxxxx; xxxxxx, krocidolitový |
12001-28-4 |
karcinogenní xxx. 1&xxxx;X |
||
|
18. |
xxxxxxxxxxx azbest; azbest, xxxxxxxxxxx |
77536-68-6 |
xxxxxxxxxxxx xxx. 1&xxxx;X |
||
|
19. |
xxxxxx |
xxxxxx |
71-43-2 |
200-753-7 |
xxxxxxxxxxxx xxx. 1&xxxx;X/ xxxxxxxxx kat. 1X |
|
20. |
xxxxx[xxx]xxxxxxx&xxxx;&xxxx;(2); xxxxx[xxx]xxxxxxxx |
xxxxx[xxx]xxxxxxx; xxxxx[x]xxxxx |
50-32-8 |
200-028-5 |
xxxxxxxxxxxx xxx. 1X/xxxxxxxxx xxx. 1X/ xxxxxxx xxx reprodukci xxx. 1X |
|
21. |
xxx(2-xxxxxxxxxxxx)xxxxxx-1,2-xxxxxxxxxxxx |
xxxxxxxxxx-xxxxxx |
84-69-5 |
201-553-2 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxx zdraví), xxxxxxx xxx xxxxxxxxxx kat. 1X |
|
22. |
xxxxxxxx xxxxxx |
xxxxxxxx xxxxxx |
10043-35-3 11113-50-1 |
233-139-2 234-343-4 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
23. |
xxxxxxxxxxx disodný |
oktaboritan disodný; xxxxxxxxxxx disodný, xxxxxxx |
12008-41-2 |
234-541-0 |
xxxxxxx xxx reprodukci kat. 1X |
|
24. |
xxxxxxxxxxx xxxxxxx, xxxxxxxxxxx |
xxxxxxxx xxxxxx, xxxxxxx xxx, xxxxxxxxxxx |
12280-03-4 |
234-541-0 |
xxxxxxx xxx reprodukci xxx. 1X |
|
25. |
xxxxxxxxxxxx xxxxxxx, xxxxxxx |
xxxxxxxxxxxx xxxxxxx, xxxxxxx; xxxxx-xxxxxxx-xxxx |
1330-43-4 |
215-540-4 |
xxxxxxx xxx xxxxxxxxxx kat. 1X |
|
26. |
xxxxxxxxxxxx disodný, xxxxxxxxxx |
xxxxx |
1303-96-4 |
215-540-4 |
xxxxxxx xxx xxxxxxxxxx kat. 1X |
|
27. |
xxxxxxxxxxxx xxxxxxx, pentahydrát |
borum-natrium-oxid, xxxxxxxxxxx |
12179-04-3 |
215-540-4 |
xxxxxxx pro reprodukci xxx. 1X |
|
28. |
xxxxxxxx xxxxxxxxxxx, xxxxx xxx |
xxxxxxxx xxxxxxxxxxx, xxxxx sůl; kyselina xxxxxx, xxxxx sůl |
13840-56-7 |
237-560-2 |
toxické xxx reprodukci xxx. 1X |
|
29. |
xxxxxxxxxxxx xxxxxxx, xxxxxxxxxx |
xxxxxxxxxxxx xxxxxxx, monohydrát; borum-natrium-oxid, xxxxxxxxxx |
12267-73-1 |
235-541-3 |
xxxxxxx xxx reprodukci kat. 1X |
|
30. |
xxxx-1,3-xxxx |
xxxx-1,3-xxxx; 1,3-xxxxxxxx |
106-99-0 |
203-450-8 |
xxxxxxxxxxxx xxx. 1&xxxx;X/ xxxxxxxxx xxx. 1X |
|
31. |
xxxxx xxxxxxxxxx ≥&xxxx;0,1&xxxx;% xxxxxxxxx (x.&xxxx;XX 203-450-8) |
xxxxx |
106-97-8 |
203-448-7 |
xxxxxxxxxxxx xxx. 1&xxxx;X |
|
32. |
xxxxxx(xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx-xxxxxxxxxxxx), (xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx-xxxxxxxxxxxx) |
xxxxxxxx, X,X“’-1,6-xxxxxxxxxxxx[X’-xxxxx-, xxxxxxx x&xxxx;1,6-xxxxxxxxxxxxx, xxxxxxxxxxxx; xxxx[xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx-1,6-xxxxxxxxx], xxxxxxxxxxxx; xxxxxxxx, X-xxxxx-, xxxxx. x&xxxx;1,6-xxxxxxxxxxxxx (2:1), xxxxxxx x&xxxx;1,6-xxxxxxxxxxxxx, xxxxxxxxxxxx (1:2); XXXX |
27083-27-8 x 32289-58-0 x 1802181-67-4 |
xxxxxxxxxxx xxx xxxxxxx v biocidních xxxxxxxxxxx xxxx 6 (xxxxxxxxxxx xxx výrobky x&xxxx;xxxxxxxxxx xxxxxxx) |
|
|
33. |
xxxxxxx-xxxxxx |
x-xxxxx-xxxxxx; xxxxxxx-xxxxxx-1,2-xxxxxxxxxxxx |
84-74-2 |
201-557-4 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx REACH – xxxxxx xxxxxx), xxxxxxx xxx reprodukci xxx. 1X |
|
34. |
xxxxxxxxx (ropné), hydrogenované xxxxx xxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% hmotnostních xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx postupem XX 346) |
64742-52-5 |
265-155-0 |
xxxxxxxxxxxx xxx. 1X |
|
|
35. |
xxxxxxxxx (xxxxx), xxxxxxxxxxxxx xxxxx parafinické x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx xxxxxxxx XX 346) |
64742-54-7 |
265-157-1 |
karcinogenní kat. 1X |
|
|
36. |
xxxxxxxxx (xxxxx), xxxxxxxxxxxxx xxxxx xxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% hmotnostních xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx xxxxxxxx XX 346) |
64742-53-6 |
265-156-6 |
karcinogenní xxx. 1X |
|
|
37. |
xxxxxxxxx (ropné), hydrogenované xxxxx xxxxxxxxxxx s obsahem ≥&xxxx;3,0&xxxx;% hmotnostních xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx xxxxxxxx XX 346) |
64742-55-8 |
265-158-7 |
xxxxxxxxxxxx kat. 1X |
|
|
38. |
xxxxxxxxx (ropné), rozpouštědlově xxxxxxxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx extrahovatelných xx xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx xxxxxxxx XX 346) |
64742-65-0 |
265-169-7 |
xxxxxxxxxxxx xxx. 1X |
|
|
39. |
xxxxxxxxx (ropné), xxxxxxxxxxxxxx rafinované těžké xxxxxxxxxxx s obsahem ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (DMSO) (xxxxxxxxx xxxxxxxx XX 346) |
64741-88-4 |
265-090-8 |
xxxxxxxxxxxx xxx. 1B |
|
|
40. |
destiláty (xxxxx), rozpouštědlově xxxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx do dimethylsulfoxidu (XXXX) (stanovení postupem XX 346) |
64741-89-5 |
265-091-3 |
karcinogenní kat. 1X |
|
|
41. |
xxxxxxxxxxx |
xxxxxxxxxxx; xxxxxx; xxxxxxxxxx |
75-21-8 |
200-849-9 |
xxxxxxxxxxxx xxx. 1X/ xxxxxxxxx xxx. 1X |
|
42. |
xxxxxxxxxxx |
xxxxxxxxxxx; xxxxxxxx; xxxxxxxx; xxxxxx |
50-00-0 |
200-001-8 |
xxxxxxxxxxxx kat. 1X |
|
43. |
xxxxxxxx |
xxxxxxxx; xxxxxxxxxx |
75-12-7 |
200-842-0 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
44. |
xxxxxxxx (obsahující ≥&xxxx;0,1&xxxx;% xxxxxxxxx (x.&xxxx;XX 203-450-8)) |
xxxxxxxx; propan, 2-xxxxxx- |
75-28-5 |
200-857-2 |
xxxxxxxxxxxx xxx. 1 A/ mutagenní kat. 1X |
|
45. |
xxxxxx xxxxx (ropné), X20–50, xxxxxxxxxxxxx xxxxxxxxx xxxxx, xxxxxxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx látek xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx postupem XX 346) |
72623-85-9 |
276-736-3 |
xxxxxxxxxxxx xxx. 1X |
|
|
46. |
xxxxxx xxxxx (ropné), X15–30, xxxxxxxxxxxxx neutrální xxxxx, x&xxxx;xxxxxxx ≥ 3,0 % xxxxxxxxxxxx xxxxx extrahovatelných xx dimethylsulfoxidu (XXXX) (xxxxxxxxx postupem XX 346) |
72623-86-0 |
276-737-9 |
xxxxxxxxxxxx xxx. 1B |
|
|
47. |
mazací xxxxx (xxxxx), X20–50, xxxxxxxxxxxxx neutrální xxxxx, x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% hmotnostních xxxxx xxxxxxxxxxxxxxxx do xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx xxxxxxxx IP 346) |
72623-87-1 |
276-738-4 |
karcinogenní xxx. 1B |
|
|
48. |
mazací xxxxx (xxxxx), X17–32, xxxxxxxxxxxxxx xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx, x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (DMSO) (xxxxxxxxx xxxxxxxx XX 346) |
101316-70-5 |
309-875-6 |
karcinogenní xxx. 1B |
|
|
49. |
benzínová xxxxxx (xxxxx), xxxxx alkylát, xxxxxxxx xxxxxxxxxx xxxxxxx X9–X12, x&xxxx;xxxxxxx ≥&xxxx;0,1&xxxx;% xxxxxxx (č. ES 200-753-7) |
64741-65-7 |
265-067-2 |
karcinogenní xxx. 1X/ xxxxxxxxx xxx. 1X |
|
|
50. |
xxxxxxxxx xxxxxx (xxxxx), xxxxxxxxxxxx xxxxxxxx těžká, xxxxxxxx X7–X12, s obsahem ≥&xxxx;0,1&xxxx;% xxxxxxx (x.&xxxx;XX 200-753-7) |
64742-82-1 |
265-185-4 |
xxxxxxxxxxxx xxx. 1&xxxx;X/ xxxxxxxxx xxx. 1X |
|
|
51. |
xxxxxxxxx xxxxxx (xxxxx), xxxxxxxxxxxx odsířená xxxxx, xxxxxxxxxxxxxxx, xxxxxxxx x&xxxx;xxxxxxxx x&xxxx;xxxxxxxxxxxxx C7, x&xxxx;xxxxxxx ≥&xxxx;0,1&xxxx;% xxxxxxx (x.&xxxx;XX 200-753-7) |
92045-53-9 |
295-434-2 |
xxxxxxxxxxxx kat. 1&xxxx;X/ xxxxxxxxx xxx. 1X |
|
|
52. |
xxxxxxxxx xxxxxx (ropná), hydrogenovaná xxxxx, převážně C6–C13, x&xxxx;xxxxxxx ≥&xxxx;0,1&xxxx;% xxxxxxx (x.&xxxx;XX 200-753-7) |
64742-48-9 |
265-150-3 |
xxxxxxxxxxxx kat. 1&xxxx;X/ xxxxxxxxx xxx. 1B |
|
|
53. |
benzínová xxxxxx (xxxxx), xxxxx xxxxxxxxxx, převážně C8–C10, x&xxxx;xxxxxxx ≥ 0,1 % benzenu (x.&xxxx;XX 200-753-7) |
64742-95-6 |
265-199-0 |
karcinogenní kat. 1&xxxx;X/ xxxxxxxxx kat. 1X |
|
|
54. |
xxxxxxxxxxx |
xxxxxxxxxxx; xxxxxx, xxxxx- |
98-95-3 |
202-716-0 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
55. |
X-xxxxxxxxxxxxxx |
X-xxxxxxxxxxxxxx; formamid, X-xxxxxx- |
123-39-7 |
204-624-6 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
56. |
xxxxxxxxxxx: xxxxx x&xxxx;xxxxxxxxx x/xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx x&xxxx;xxxxxx 9 xxxxxx xxxxxxxxxx xxxxxxxx x&xxxx;xxxxxxx xx xxxxxxxxx xxxxxx, xxxxxxxxxx xxxxxx xxxxx, xxxxx obsahují xxxxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxxx |
4-(3,5-xxxxxxxxxxxxxx-3-xx)xxxxx; xxxxx, 4-(1-xxxxx-1,3-xxxxxxxxxxxxxx)-; 4-(1-xxxxx-1,3-xxxxxxxxxxxxxx)xxxxx |
186825-36-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
57. |
4-(3,6-xxxxxxxxxxxxxx-3-xx)xxxxx; xxxxx, 4-(1-xxxxx-1,4-xxxxxxxxxxxxxx)-; 4-(1-xxxxx-1,4-xxxxxxxxxxxxxx)xxxxx |
142731-63-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 písm. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
58. |
4-(2-xxxxxxxxxxx-2-xx)xxxxx; x-(1,1-xxxxxxxxxxxxxx)xxxxx; xxxxx, 4-(1,1-xxxxxxxxxxxxxx)- |
30784-30-6 |
250-339-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení REACH – xxxxxxx xxxxxxxxx) |
|
|
59. |
4-(3-xxxxxxxxxxx-3-xx)xxxxx; xxxxx, 4-(1-xxxxx-1-xxxxxxxxxxx)-; 4-(1-xxxxx-1-xxxxxxxxxxx)xxxxx |
52427-13-1 |
257-907-1 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
60. |
4-xxxxxxxxxx x-xxxxxxxxxx; xxxxx, 4-xxxxx- |
104-40-5 |
203-199-4 |
xxxxxxxxxx vyvolávající xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
|
|
61. |
xxxxxxxxxxxxx |
11066-49-2 |
234-284-4 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
62. |
p-isononylfenol; fenol, 4-xxxxxxxx- |
26543-97-5 |
247-770-6 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
63. |
nonylfenol; fenol, xxxxx- |
25154-52-3 |
246-672-0 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
64. |
xxxxx, 4-(1-xxxxxxxxxxx)-; x-(1-xxxxxxxxxxx)xxxxx |
17404-66-9 |
241-427-4 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
65. |
fenol, 4-nonyl-, xxxxxxxxxx |
84852-15-3 |
284-325-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
66. |
xxxxx, nonyl-, xxxxxxxxxx |
90481-04-2 |
291-844-0 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) nařízení XXXXX – xxxxxxx prostředí) |
|
|
67. |
nonylfenoly, xxxxxxxxxxxx: xxxxx x&xxxx;xxxxxxxxx x/xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx x&xxxx;xxxxxx 9 xxxxxx xxxxxxxxxx vázaných x&xxxx;xxxxxxx xx xxxxxxxxx pozici, xxxxxxxxxxxx, xxxxxxxxxx rovněž xxxxx, xxxxx xxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxxx |
xxxxxxxxxx, xxxxxxxxxxxx; xxxx(xxx-1,2-xxxxxxxxx), α-(xxxxxxxxxx)-ω-xxxxxxx- |
500-024-6 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
68. |
4-xxxxxxxxxx, rozvětvený, xxxxxxxxxxxx, 1–2,5 mol; poly(oxy-1,2-ethandiyl), α-(4-xxxxxxxxxx)-ω-xxxxxxx-, xxxxxxxxxx |
500-315-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
69. |
4-xxxxxxxxxx, ethoxylovaný, 1–2,5 xxx |
500-045-0 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 písm. x) xxxxxxxx REACH – xxxxxxx prostředí) |
||
|
70. |
2-(2-{2-[2-(4-nonylfenoxy)ethoxy]ethoxy}ethoxy)ethan-1-ol; 2-[2-[2-[2-(4-nonylfenoxy)ethoxy]ethoxy]ethoxy]ethanol; ethanol, 2-[2-[2-[2-(4-nonylfenoxy)ethoxy]ethoxy]ethoxy]- |
7311-27-5 |
230-770-5 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
|
|
71. |
2-[2-(4-xxxxxxxxxxx)xxxxxx]xxxxxxx; xxxxxxx, 2-[2-(4-xxxxxxxxxxx)xxxxxx]- |
20427-84-3 |
243-816-4 |
xxxxxxxxxx vyvolávající narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – životní xxxxxxxxx) |
|
|
72. |
20-(4-xxxxxxxxxxx)-3,6,9,12,15,18-xxxxxxxxxxxxx-1-xx; 3,6,9,12,15,18-xxxxxxxxxxxxxx-1-xx, 20-(4-xxxxxxxxxxx)- |
27942-27-4 |
248-743-1 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
|
|
73. |
2-[2-[2-[2-(4-xxxxxxxxxxx)xxxxxx]xxxxxx]xxxxxx]xxxxx-1-xx; xxxxxxx, 2-[2-[2-[2-(4-nonylfenoxy)ethoxy]ethoxy]ethoxy]- |
7311-27-5 |
vlastnosti xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
74. |
26-(4-xxxxxxxxxxx)-3,6,9,12,15,18,21,24-xxxxxxxxxxxxxxxx-1-xx; 3,6,9,12,15,18,21,24-xxxxxxxxxxxxxxxx-1-xx, 26-(4-xxxxxxxxxxx)- |
14409-72-4 |
xxxxxxxxxx vyvolávající narušení xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
75. |
17-(4-xxxxxxxxxxx)-3,6,9,12,15-xxxxxxxxxxxxxxxxxx-1-xx; 3,6,9,12,15-xxxxxxxxxxxxxxxxxx-1-xx, 17-(4-nonylfenoxy)- |
34166-38-6 |
vlastnosti vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
||
|
76. |
xxxx(xxx-1,2-xxxxxxxxx), α-(4-xxxxxxxxxx)-ω-xxxxxxx-, xxxxxxxxxx |
127087-87-0 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
77. |
xxxx(xxx-1,2-xxxxxxxxx), α-(4-xxxxxxxxxx)-ω-xxxxxxx- |
26027-38-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
78. |
ethanol, 2-(4-xxxxxxxxxxx)- |
104-35-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
79. |
isononylfenol, xxxxxxxxxxxx; xxxx(xxx-1,2-xxxxxxxxx), α-(isononylfenyl)-ω-hydroxy- |
37205-87-1 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
80. |
2-[2-(4-xxxx-xxxxxxxxxxx)xxxxxx]xxxxxxx; xxxxxxx, 2-[2-(4-terc-nonylfenoxy)ethoxy]- |
156609-10-8 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) nařízení XXXXX – životní xxxxxxxxx) |
||
|
81. |
xxxx(xxx-1,2-xxxxxxxxx), α-(xxxxxxxxxx)-ω-xxxxxxx- xxxxxxxxxx, xxxxxxxxxxxx |
9016-45-9 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
82. |
oktylfenoly: látky x&xxxx;xxxxxxxxx x/xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx x&xxxx;xxxxxx 8 xxxxxx kovalentně xxxxxxxx x&xxxx;xxxxxxx na jakékoliv xxxxxx, zahrnující xxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxx xxxx jejich xxxxxxxxx |
x-xxxxxxxxxx; 4-xxxxxxxxxx |
1806-26-4 |
217-302-5 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx REACH – xxxxxxx prostředí) |
|
83. |
4-(2,4,4-trimethylpentan-2-yl)fenol; 4-(1,1,3,3-tetramethylbutyl)fenol; 4-(terc-oktyl)fenol; fenol, 4-(1,1,3,3-xxxxxxxxxxxxxxxx)-; 4-xxxx-xxxxxxxxxx |
140-66-9 |
205-426-2 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
|
|
84. |
xxxxxxxxxx; xxxxx, oktyl- |
67554-50-1 |
266-717-8 |
vlastnosti vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
85. |
xxxxx, 2-xxxxxxxx- |
86378-08-7 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
||
|
86. |
xxxxx, xxxxxxxx-; xxxxxxxxxxxxx |
11081-15-5 |
234-304-1 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
87. |
xxxxx, 2-oktyl-; o-oktylfenol |
949-13-3 |
213-437-9 |
vlastnosti vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
88. |
fenol, 2-sek-oktyl-; o-sek-oktylfenol |
26401-75-2 |
247-663-4 |
vlastnosti xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (čl. 57 písm. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
89. |
xxxxx, 4-xxxxxxxx-; x-xxxxxxxxxxxxx |
27013-89-4 |
248-164-4 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
90. |
xxxxx, 4-xxx-xxxxx-; x-xxx-xxxxxxxxxx |
27214-47-7 |
248-330-6 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
91. |
fenol, xxx-xxxxx-; xxx-xxxxxxxxxx |
93891-78-2 |
299-461-0 |
xxxxxxxxxx xxxxxxxxxxxx narušení endokrinní xxxxxxxx (čl. 57 písm. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
92. |
xxxxx, 4-(1-xxxxxxxxxx)-; x-(1-xxxxxxxxxx)xxxxx |
3307-00-4 |
221-989-7 |
xxxxxxxxxx vyvolávající narušení xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
|
|
93. |
xxxxx, 2-(1-xxxxxxxxxxxxxx)-; x-(1-xxxxxxxxxxxx)xxxxx |
18626-98-7 |
242-459-1 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 písm. f) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
94. |
fenol, 2-(1-xxxxxxxxxx)-; x-(1-xxxxxxxxxx)xxxxx |
17404-44-3 |
241-426-9 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení REACH – xxxxxxx xxxxxxxxx) |
|
|
95. |
xxxxx, 2-(1-xxxxxxxxxxxx)-; x-(1-xxxxxxxxxxxx)xxxxx |
37631-10-0 |
253-574-1 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
96. |
xxxxx, 4-(1-xxxxxxxxxxxx)-; x-(1-xxxxxxxxxxxx)xxxxx |
3307-01-5 |
221-990-2 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
97. |
fenol, 2-(1-xxxxxxxxxxxx)-; x-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx |
3884-95-5 |
223-420-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx prostředí) |
|
|
98. |
fenol, (1,1,3,3-xxxxxxxxxxxxxxxx)-; (1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx |
27193-28-8 |
248-310-7 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (čl. 57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
|
|
99. |
xxxxx, (1-xxxxxxxxxxxx)-; (1-xxxxxxxxxxxx)xxxxx |
27985-70-2 |
248-759-9 |
xxxxxxxxxx vyvolávající xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
100. |
xxxxx, 4-(2-xxxxxxxxxxxx)- |
898546-19-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – životní xxxxxxxxx) |
||
|
101. |
xxxxx, 2-(2-xxxxxxxxxx)- |
28752-62-7 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
||
|
102. |
xxxxx, 4-(1-methylheptyl)-; p-(1-methylheptyl)fenol |
1818-08-2 |
217-332-9 |
vlastnosti vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
103. |
xxxxx, 4-(2-xxxxxxxxxx)- |
69468-20-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
104. |
fenol, 4-(5-xxxxxxxxxxxx)- |
1824164-95-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
105. |
xxxxx, 2-(2-xxxxxxxxxxxx)- |
898546-20-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
106. |
fenol, 4-(2-xxxxxxxxxxxx)- |
119747-99-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (čl. 57 xxxx. x) nařízení XXXXX – xxxxxxx prostředí) |
||
|
107. |
fenol, 3-xxxxx- |
20056-69-3 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) nařízení XXXXX – životní xxxxxxxxx) |
||
|
108. |
xxxxx, 2-(1,1-dimethylhexyl)- |
1824575-79-2 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
||
|
109. |
xxxxx, 4-(1,1-xxxxxxxxxxxxx)- |
30784-29-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
110. |
xxxxx, 4-(5,5-xxxxxxxxxxxxx)- |
13330-52-4 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
111. |
xxxxx, 2-(5,5-xxxxxxxxxxxxx)- |
1822989-97-8 |
xxxxxxxxxx vyvolávající xxxxxxxx endokrinní činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
112. |
fenol, 3-(1,1-dimethylhexyl)- |
70435-92-6 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
113. |
xxxxx, 4-(1,4-xxxxxxxxxxxxx)- |
164219-26-5 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
114. |
xxxxxxxxxxx, xxxxxxxxxxxx: xxxxx x&xxxx;xxxxxxxxx x/xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx x&xxxx;xxxxxx 8 xxxxxx kovalentně xxxxxxxx x&xxxx;xxxxxxx na jakékoliv xxxxxx, ethoxylované, xxxxxxxxxx xxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxxx |
xxxx(xxx-1,2-xxxxxxxxx), α-[(1,1,3,3-tetramethylbutyl)fenyl]-ω-hydroxy-; 2-(2-[4-(1,1,3,3-tetramethylbutyl)fenoxy]ethoxy)ethanol; polyethylenglykoloktylfenylether |
9036-19-5 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
115. |
2-[4-(2,4,4-xxxxxxxxxxxxxxx-2-xx)xxxxxx]xxxxxxx; xxxx(xxx-1,2-xxxxxxxxx), α-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx]-ω-xxxxxxx-; xxxxxxxxxx, xxxxxxxxxxxx |
9002-93-1 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (čl. 57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
116. |
20-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]-3,6,9,12,15,18-xxxxxxxxxxxxx-1-xx; 3,6,9,12,15,18-xxxxxxxxxxxxxx-1-xx, 20-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
2497-59-8 |
219-682-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
117. |
xxxxxxx, 2-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
2315-67-5 |
xxxxxxxxxx xxxxxxxxxxxx narušení endokrinní xxxxxxxx (xx.&xxxx;57 písm. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
||
|
118. |
xxxxxxx, 2-[2-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]xxxxxx]- |
2315-61-9 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. f) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
119. |
3,6,9,12,15,18,21,24-xxxxxxxxxxxxxxxx-1-xx, 26-(4-xxxxxxxxxxx)- |
42173-90-0 |
255-695-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
120. |
xxxx(xxx-1,2-xxxxxxxxx), α-(xxxxxxxxxx)-ω-xxxxxxx-, xxxxxxxxxx |
68987-90-6 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
121. |
xxxx(xxx-1,2-xxxxxxxxx), α-[4-(6-methylheptyl)fenyl]-ω-hydroxy- |
59379-12-3 |
vlastnosti xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
122. |
ethanol, 2-(4-xxxxxxxxxxx)-; 2-(x-xxxxxxxxxxx)xxxxxxx |
51437-89-9 |
257-203-4 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – životní xxxxxxxxx) |
|
|
123. |
xxxx(xxx-1,2-xxxxxxxxx), α-(4-xxxxxxxxxx)-ω-xxxxxxx- |
26636-32-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
||
|
124. |
xxxx(xxx-1,2-xxxxxxxxx), α-[4-(1-xxxxxxxxxxxx)xxxxx]-ω-xxxxxxx- |
73935-42-9 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. f) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
125. |
3,6,9,12,15,18-hexaoxaeikosan-1-ol, 20-(4-oktylfenoxy)-; 20-(4-oktylfenoxy)-3,6,9,12,15,18-hexaoxaikosan-1-ol |
32742-88-4 |
251-190-9 |
vlastnosti xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
126. |
xxxxxxx, 2-[2-[2-[2-(4-xxxxxxxxxxx)xxxxxx]xxxxxx]xxxxxx]-; 2-(x-xxxxxxxxxxx)xxxxxxx |
51437-92-4 |
xxxxxxxxxx vyvolávající narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
127. |
xxxxxxx, 2-[2-(4-oktylfenoxy)ethoxy]- |
51437-90-2 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
||
|
128. |
3,6,9,12,15-xxxxxxxxxxxxxxxxxx-1-xx, 17-(4-oktylfenoxy)- |
51437-94-6 |
vlastnosti xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx prostředí) |
||
|
129. |
poly(oxy-1,2-ethandiyl), α-(xxxxxxxxxxxxx)-ω-xxxxxxx- |
9004-87-9 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
130. |
2-[2-[2-(4-xxxxxxxxxxx)xxxxxx]xxxxxx]xxxxxxx |
51437-91-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
131. |
3,6,9,12,15-xxxxxxxxxxxxxxxxxx-1-xx, 17-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
2497-58-7 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
132. |
xxxxxxx, 2-[2-[2-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]xxxxxx]xxxxxx]- |
2315-62-0 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
||
|
133. |
xxxxxxx, 2-[2-[2-[2-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]xxxxxx]xxxxxx]xxxxxx]- |
2315-63-1 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
134. |
3,6,9,12-xxxxxxxxxxxxxxxxxx-1-xx, 14-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
2315-64-2 |
xxxxxxxxxx vyvolávající xxxxxxxx endokrinní činnosti (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
135. |
3,6,9,12,15,18,21,24-oktaoxahexakosan-1-ol, 26-[4-(1,1,3,3-tetramethylbutyl)fenoxy]- |
2315-65-3 |
vlastnosti xxxxxxxxxxxx narušení endokrinní xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
136. |
3,6,9,12,15,18,21,24,27-xxxxxxxxxxxxxxxx-1-xx, 29-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
2315-66-4 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx činnosti (čl. 57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
137. |
xxxxxxx, 2-[3-(1,1,3,3-tetramethylbutyl)fenoxy]- |
1026254-24-9 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
138. |
xxxxxxx, 2-[2-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
84658-53-7 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
139. |
xxxxxxx, 2-[2-(xxxxxxxxxxx)xxxxxx]- |
27176-92-7 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
140. |
X,X-xxxxxxxxxxxxxxxx |
X,X-xxxxxxxxxxxxxxxx; dimethylformamid; XXX |
68-12-2 |
200-679-5 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
141. |
xxxx-2-xxxxxx |
xxxxxxxxx; 2-xxxxxxxxxx |
79-06-1 |
201-173-7 |
xxxxxxxxxxxx kat. 1X/ xxxxxxxxx kat. 1B |
|
142. |
pyridin, xxxxxxxxxxxxx, x&xxxx;xxxxxxx ≥&xxxx;0,1&xxxx;% xxxxxxx (x.&xxxx;XX 200-753-7) |
68391-11-7 |
269-929-9 |
xxxxxxxxxxxx xxx. 1 A/ mutagenní xxx. 1X |
|
|
143. |
xxxxxxxx |
xxxxxxxx |
91-22-5 |
202-051-6 |
xxxxxxxxxxxx kat. 1X |
|
144. |
xxxxxxxxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxxxxxxx; 2-xxxxxxxxxxxxx, xxxxxxxxxx- |
97-99-4 |
202-625-6 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
(1)&xxxx;&xxxx;Xxxxx xxx xxxxxxxxxxx xxxxxxxxxx látek xxxxxxxxx v tabulce xxxx xxxxxxxxx xxxxxxxxx v konečném xxxxxxxxx xxxx 0,1 % (xxxxxxxxxxxx (xxxx.)), není-li x&xxxx;xxxx xxxxxxx xxxxxxx xxxxx.
(2)&xxxx;&xxxx;Xxxxx xxx přijatelnou xxxxxxxxxx xxxx látky xxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx xxxx 0,01&xxxx;% (hmotnostních (xxxx.)), xxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx stanovenému x&xxxx;xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008.